Biotech Values

[biocqr]

MEIP - MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome

Data from Three Ongoing Phase II Trials of Pracinostat Anticipated by Year End

SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to respond or maintain a response to a hypomethylating agent (HMA) alone.

http://www.nasdaq.com/press-release/mei-pharma-initiates-phase-ii-clinical-trial-of-pracinostat-in-refractory-myelodysplastic-syndrome-20140114-00591